NCT00760578View on ClinicalTrials.gov

A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

February 28, 2009

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Placebo

Once daily, oral

DRUG

Pioglitazone

Once daily, oral

DRUG

MSDC-0160 90 mg

Once daily, oral

DRUG

MSDC-0160 220 mg

Once daily, oral

Trial Locations (8)

Unknown

Los Angeles

Miami Gardens

West Palm Beach

Kalamazoo

Greenville

Dallas

San Antonio

Renton

Sponsors
All Listed Sponsors
lead

Metabolic Solutions Development Company

INDUSTRY

NCT00760578 - A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator | Biotech Hunter | Biotech Hunter